Safety concerns about digoxin after acute myocardial infarction

Lancet

Volumn 354, Issue 9176, 1999, Pages 391-392

  Spargias, Konstantinos S ^a   Hall, Alistair S ^a   Ball, Stephen G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0033620796     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)01429-4     Document Type: Article

References (5)

1. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
2. Gheorghiade M. A symposium: management of heart failure in the 1990s: a reassessment of the role of digoxin therapy. Am J Cardiol. 691-154:1992.
3. Iesaka Y., Aonuma K., Gosselin A.J.et al. Susceptibility of infarcted canine hearts to digitalis-toxic ventricular tachycardia. J Am Coll Cardiol. 2:1983;45-51.
4. McClements B.M., Adgey A.A.J. Value of signal-averaged electrocardiolography, radionuclide ventriculopathy, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thombolytic era. J Am Coll Cardiol. 21:1993;1419-1427.
5. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 343:1993;818-821.